CytoCore (OTCMKTS:MDIT) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Tuesday.

Shares of CytoCore (OTCMKTS:MDIT) opened at $0.43 on Tuesday. CytoCore has a 1-year low of $0.25 and a 1-year high of $0.88. The company has a quick ratio of 0.69, a current ratio of 1.54 and a debt-to-equity ratio of 0.64.

ILLEGAL ACTIVITY WARNING: “ValuEngine Upgrades CytoCore (MDIT) to “Buy”” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/valuengine-upgrades-cytocore-mdit-to-buy/1762481.html.

CytoCore Company Profile

MEDITE Cancer Diagnostics, Inc (MEDITE), formerly CytoCore, Inc, is a medical technology company engaged in the development, engineering, manufacturing and marketing of molecular biomarkers and medical devices and consumables for detection, risk assessment and diagnosis of cancer, precancerous conditions and related diseases.

Receive News & Ratings for CytoCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoCore and related companies with MarketBeat.com's FREE daily email newsletter.